Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today issued a video letter to its shareholders from Chairman and Chief Executive Officer, Walter Klemp , which includes an update on its current activities.
March 4, 2020
· 3 min read